reference/2007088

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2007088

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	2168
issn	0140-6736
issueIdentifier	10290
pageRange	2151-2168
publicationName	Lancet (London, England)
startingPage	2151
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_92189241639fdfe4c43533b4d19c157b
bibliographicCitation	Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 05;397(10290):2151–68. doi: 10.1016/s0140-6736(21)00588-2. PMID: 34023008.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9370-3279 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6dfae42f0a133d66d32b2b0e9b61532 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5f68d527feb517c07434e043b8dc7bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1090d0a7f1d45b2509f3998e53330764 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e6a78682b3cc62857cf99510db6ef4b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c419b247f509ab7ed0493ccb9179aa97 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63d67d3087a77cbb023a76680103346d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98aaa5e47d3deaa7bb2b0d3cb809280a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59b6d4f7bfefa8df25956fc7bdfeb9b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4fc849133a7f38e0838f13921628b83 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b55b01636f71103a32204496f240519 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_adb7c47f4134d2223c7d678c65a00d46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_432ee1a2cc3105280b4fef371116bc62 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e42b54275927493d8580efaa46e9d831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f60bd352c852c03727d0deef97f00262 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7144fa77f2936f5d19bb7481fc4aa9ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86c8850579a4dc2b4e586313aaf98e1d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89d2cd84be28ac0b1cdc94b0a2a1ac9c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab0514287ccde565dee98c1c037bb75f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_460e4062e712e183b67e08039c43f21a
date	2021-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/34023008 https://doi.org/10.1016/s0140-6736%2821%2900588-2
isPartOf	https://portal.issn.org/resource/ISSN/0140-6736 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5470
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
discusses	http://id.nlm.nih.gov/mesh/M0010294 http://id.nlm.nih.gov/mesh/M0203027 http://id.nlm.nih.gov/mesh/M0473764 http://id.nlm.nih.gov/mesh/M000646360 http://id.nlm.nih.gov/mesh/M000630004
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000075242Q000627 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D003876Q000188 http://id.nlm.nih.gov/mesh/D012720 http://id.nlm.nih.gov/mesh/D006575Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D000075242Q000008 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D006575Q000008 http://id.nlm.nih.gov/mesh/D053613 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID586 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8592 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7547 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_335366b86eab13ea9f6925279dca28aa http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58557659 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9083 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8995 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6777 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7433 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_44bbfcd49d7873a592f5d68d29a0784d http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_54e32599939667ce8030f6c1725ceac0 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_80f54de8de1372a44929c8de57e0d3b9

Total number of triples: 73.